COMPANY - ABOUT US

Tikcro Technologies:
Tikcro has holdings in BioCancell Therapeutics, Inc., a clinical-stage biopharmaceutical company operating in the area of cancer treatment.

BioCancell is conducting the following clinical trials in Israel and in the U.S. using its leading drug, BC-819:
- Phase IIb clinical trial for the treatment of superficial bladder carcinoma cancer.
- Phase I/IIa clinical trial for the treatment of ovarian cancer
- Phase I/IIa clinical trial for the treatment of pancreatic cancer.

Tikcro holds 35% of Biocancell (after conversion of notes and exercise of warrants), and 26% on a fully diluted basis.

Tikcro is headquartered in Tel Aviv, Israel.